Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. | LinkedIn
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Puma Biotechnology Inc
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
Puma Biotechnology
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology
Why Puma Biotechnology Shares Dropped 17.7% This Week | The Motley Fool
PumaBiotech (@pumabiotech) / Twitter
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
